Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Core Viewpoint - Tiziana Life Sciences has regained compliance with Nasdaq's minimum bid price requirement, allowing its common stock to continue trading on the Nasdaq Capital Market [1][2]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies, particularly through intranasal administration [5]. - The company's lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [5]. Product Development - Foralumab has been shown to stimulate T regulatory cells when administered intranasally, with positive outcomes observed in patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) [3]. - An open-label intermediate sized Expanded Access Program has dosed 10 patients, all of whom exhibited either improvement or stability of disease within six months [3]. - The FDA has approved the enrollment of an additional 20 patients in this program, and a Phase 2a trial is currently underway [3][4]. Mechanism of Action - Foralumab works by binding to the T cell receptor, modulating T cell function, and dampening inflammation, which is beneficial in treating conditions like COVID-19 and multiple sclerosis [4]. - The nasal administration of anti-CD3 monoclonal antibodies represents a novel approach for treating neuroinflammatory and neurodegenerative diseases [4].